Bára Cihlová is a young Czech scientist who has been admitted to Oxford University to study viral enzymes. Unfortunately, the studies in Oxford are not just extremely difficult but also financially demanding, especially after Brexit when the fees for EU-based students quadrupled. Thus, Bára decided to raise money for her studies by an unconvential but efficient way – crowdfunding https://www.donio.cz/baracihlova.

Enantis decided to support her campaign financially and would like to highlight this case to other individuals and companies who might be able to help this bright student. Who knows, maybe Bára will make a breakthrough in her science career and help us all in return!

A few months ago, we have announced the successful licensing of our innovative product, FGF2-STAB, to a global partner in stem cell culturing reagents business. Our patented molecule has been improved by protein engineering approaches to achieve elevated thermostability and to retain its biological activity for longer time.

The story of how it happened, what exactly are the licensed growth factors and what it means for both Enantis and Masaryk University has been published and is available here:

https://lnkd.in/dyZwV2q

#biotech #licensing #proteinengineering #cellculture #stemcells #brnoregion

Protein engineering course

After the last year’s successful event, Loschmidt Laboratories and Enantis organise another Hands-on Computational Enzyme Design Course

The first event was really popular and Enantis gained valuable customers who decided to source the professional versions of software from us. The list of software we provide can be found here: https://lnkd.in/dBqUXWg

We are looking forward to online-meet this year’s cohort and hope they have a great time and learn a lot!

Here is the course website for anyone interested in attending: https://loschmidt.chemi.muni.cz/academy/

Jan Herudek joins Enantis team

Recently, there has been a new addition to Enantis team. Jan Herudek has joined our ranks as a Molecular Biologist who will be responsible for the pre-clinical testing of our engineered molecules. Jan will be a great reinforcement for Enantis team, especially as more and more of our projects are steering towards medical applications.

Jan is an accomplished scientist with a broad international experience. He has spent more than three years at the Aarhus University in Denmark studying molecular biology and genetics to help better understanding of non-coding RNAs. Also, he has been awarded prestigious grants from Boehringer Ingelheim Fonds and SoMoPro – South Moravian Programme for Distinguished Researchers aimed at scientists returning to South Moravia from research institutions abroad. Jan has joined us after spending four years at CEITEC – Central European Institute of Technology.

We hope he will be happy amongst us as we strive to have not just highly professional, but also well-balanced and friendly team.

 

#brnoregion #biotechnologies #team

TACR TREND project granted!

We couldn’t find a better way to start off 2021 at Enantis. We are happy to announce our successful grant application for TACR TREND „Technology Leaders“ programme! To our great delight, the project was ranked the second one in life science category and 14th all together from the 434 applications.

Our project will focus on development and commercialization of new stable FGF molecules from our research pipeline that are planned to be used as reagents in stem cell research. High intrinsic instability of these molecules prevents their widespread use and thanks to our collaboration with Masaryk University, we will be able to apply advanced AI-based protein engineering approaches to stabilize these innovative molecules and bring their high added value to the customers.

This grant will help Enantis broaden the product portfolio and focus on the internal R&D even in these times of uncertainty. Big thanks to the Technology Agency of the Czech Republic #TACR and everyone who contributed to this effort!

#biotech #brnoregion #proteinengineering

PF 2021

Despite 2020 being the strangest and least predictable year ever, Enantis managed to fulfil its goals.

We have managed to secure a global license agreement to reach even more customers with our FGF2-STAB in the years to come. Moreover, we have been officially granted a European patent covering the FGF2-STAB invention and more patents in other territories are pending. Also, we were working hard on other molecules from our pipeline to bring new products to the market soon.

As everyone this year, we hope 2021 proves to be game-changing and very different from 2020 and we are ready to make the best out of it.

No matter the altered circumstances, we wish you a lovely Christmas time and a happy New Year.

License Agreement Announcement

After months of negotiations, we are delighted to announce that Enantis has entered into a global license agreement with one of the top providers of life science solutions with our innovative FGF2-STAB® molecule and its use in research and cell therapy market.
“Having a licensing deal with a company from Fortune magazine’s yearly list of 500 largest US companies is a significant milestone for us,” says Roman Badik, CEO of Enantis.
Under the terms of agreement, Enantis along with Masaryk University have granted worldwide royalty-bearing license to manufacture FGF2-STAB® and develop new products containing this patented molecule. More details including the name of the licensee cannot be disclosed as per the terms of the license.

European Patent Granted

We are excited to announce that the European Patent covering the hyper stable form of FGF2 has just been granted to Enantis and Masaryk University. We have worked really hard to get here. The next step is granting of the US patent to have a full IP protection and we hope this happens soon as well.